Pearson returns to Valeant with promise to boost payer, government relations

Valeant ($VRX) CEO J. Michael Pearson, sidelined for two months with pneumonia, is back--and he's got a new set of priorities to dig his company out of its current rut. Among them: Beef up relationships with payers, regulators and government officials, he said Sunday. More from FiercePharma

Suggested Articles

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.

Bristol Myers Squibb and Exelixis will soon know whether their I-O/TKI combo gets a chance to challenge Merck and Pfizer's Keytruda-Inlyta regimen.